These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 8520368)

  • 1. Thrombolytic treatment. Streptokinase is more economical than alteplase.
    Mucklow JC
    BMJ; 1995 Dec; 311(7018):1506. PubMed ID: 8520368
    [No Abstract]   [Full Text] [Related]  

  • 2. Myocardial infarction, thrombolytic therapy, and economics.
    Shander D
    Clin Cardiol; 1993 Nov; 16(11):845. PubMed ID: 8269667
    [No Abstract]   [Full Text] [Related]  

  • 3. Study assigns dollar value to alteplase-streptokinase debate.
    Am J Health Syst Pharm; 1995 Aug; 52(15):1600. PubMed ID: 7583819
    [No Abstract]   [Full Text] [Related]  

  • 4. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction.
    Mark DB; Hlatky MA; Califf RM; Naylor CD; Lee KL; Armstrong PW; Barbash G; White H; Simoons ML; Nelson CL
    N Engl J Med; 1995 May; 332(21):1418-24. PubMed ID: 7723799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic and cost-effectiveness in evaluating the value of cardiovascular therapies. The impact of the cost-effectiveness study of GUSTO-1 on decision making with regard to fibrinolytic therapy.
    Califf RM; Stump D; Topol EJ; Mark DB
    Am Heart J; 1999 May; 137(5):S90-3. PubMed ID: 10220606
    [No Abstract]   [Full Text] [Related]  

  • 6. Pharmacoeconomic aspects of treatment of acute myocardial infarction with thrombolytic agents.
    Woo KS; White HD
    Pharmacoeconomics; 1993 Mar; 3(3):192-204. PubMed ID: 10172049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tissue plasminogen activator was cost-effective compared to streptokinase in only selected patients with acute myocardial infarction.
    Kent DM; Vijan S; Hayward RA; Griffith JL; Beshansky JR; Selker HP
    J Clin Epidemiol; 2004 Aug; 57(8):843-52. PubMed ID: 15485737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Evaluation of the cost-effectiveness of thrombolytic therapy in acute myocardial infarct using tissue plasminogen activator or streptokinase:the Italian perspective].
    Lorenzoni R; Fattore G; Gensini G
    G Ital Cardiol; 1997 Jul; 27(7):721-6. PubMed ID: 9303862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is alteplase (t-PA) more cost-effective than streptokinase?
    Sanchez LA
    Pharmacoeconomics; 1992 Nov; 2(5):427-8. PubMed ID: 10172065
    [No Abstract]   [Full Text] [Related]  

  • 10. Emergent decision-making: defining the patient perspective.
    Knudtson ML
    Can J Cardiol; 2005 Apr; 21(5):433-4. PubMed ID: 15861261
    [No Abstract]   [Full Text] [Related]  

  • 11. Choice of agent for peripheral thrombolysis.
    Buckenham TM
    Br J Surg; 1993 Jun; 80(6):808. PubMed ID: 8330183
    [No Abstract]   [Full Text] [Related]  

  • 12. [Thrombolytic therapy in acute myocardial infarction].
    Pedersen TR
    Tidsskr Nor Laegeforen; 1994 May; 114(14):1646-7. PubMed ID: 8079271
    [No Abstract]   [Full Text] [Related]  

  • 13. Thrombolytic therapy for acute myocardial infarction.
    Clem JR
    S D J Med; 1994 Jan; 47(1):27-8. PubMed ID: 8122094
    [No Abstract]   [Full Text] [Related]  

  • 14. Cost, uncertainty, and doctors' decisions. The case of thrombolytic therapy.
    Lessler DS; Avins AL
    Arch Intern Med; 1992 Aug; 152(8):1665-72. PubMed ID: 1497400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thrombolytic therapy with alteplase for ischaemic stroke.
    Drug Ther Bull; 2009 Feb; 47(2):14-8. PubMed ID: 19193701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Who uses streptokinase vs alteplase (t-PA), and why?
    Sanchez LA
    Pharmacoeconomics; 1992 Nov; 2(5):428-9. PubMed ID: 10172066
    [No Abstract]   [Full Text] [Related]  

  • 17. Thrombolytic therapy in the elderly. Pharmacoeconomic considerations.
    Ramanathan K; Ellis CJ; White HD
    Drugs Aging; 1996 Apr; 8(4):237-44. PubMed ID: 8920173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient reperfusion preferences in acute myocardial infarction: mortality versus stroke, benefits versus costs, high technology versus drugs.
    Tsui W; Pierre K; Massel D
    Can J Cardiol; 2005 Apr; 21(5):423-31. PubMed ID: 15861260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation and comparison of the adverse effects of streptokinase and alteplase.
    Tisdale JE; Colucci RD; Ujhelyi MR; Kluger J; Fieldman A; Chow MS
    Pharmacotherapy; 1992; 12(6):440-4. PubMed ID: 1492007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regional thrombolytic infusion for peripheral arterial occlusion: is urokinase really the drug of choice?
    Weber JJ; Chong K
    Am J Health Syst Pharm; 1998 Nov; 55(22):2414-6. PubMed ID: 9825039
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.